Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / CYCN - Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

CYCN - Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Cyclerion Therapeutics Inc.
  • After two candidate failures over the past two years, Cyclerion Therapeutics, Inc. is pinning its hopes on CNS therapy CY6463.
  • The soluble guanylate cyclase modulator is currently undergoing mid-stage evaluation for one CNS indication and should enter a Phase 2 study for another in 2021.
  • With a small market cap and no clinical data due until YE21, yet significant insider buying from the CEO, this busted IPO merited a deeper dive.
  • A full investment analysis is provided in the paragraphs below.

For further details see:

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021
Stock Information
Company Name: Cyclerion Therapeutics Inc.
Stock Symbol: CYCN
Market: NYSE
Website: cyclerion.com
Menu
CYCN CYCN Quote CYCN Short CYCN News CYCN Articles CYCN Message Board
Get CYCN Alerts

News, Short Squeeze, Breakout and More Instantly...